Information provider Thomson Reuters has reinforced its decision-support offering for researchers in pharmaceutical and biotechnology companies as well as academia by acquiring US-based business GeneGo for an undisclosed sum.
Headquartered in San Diego and with offices in Michigan, US and Moscow, Russia, GeneGo is a leading provider of biology and disease information, analytics and decision-support solutions for research and development. It becomes part of Thomson Reuters’ Healthcare & Science business with immediate effect.
GeneGo’s capabilities, Thomson Reuters notes, include MetaBase, a “comprehensive and respected” knowledge base in systems biology; expertise in analytics, data management and value-added services; an experienced management and skilled scientific staff; and a successful track-record of deploying decision-support systems.
The company’s scientific expertise and assets in biology-driven drug discovery will complement the Thomson Reuters life sciences portfolio, which encompasses drug pipeline competitive intelligence, patents and chemistry, the latter adds.
“Thomson Reuters now provides comprehensive decision-support solutions to help researchers striving to bring more effective medications to market,” commented executive vice-president Jon Brett-Harris. “There is an increasing need for biology content, detailed disease insights and analytics to support R&D productivity and to enable a more personalised approach to medicine.”
GeneGo is a private company founded in 2000 by Tatiana Nikolskaya, previously a molecular biologist at the University of Chicago in the US.
The company’s data-mining tools and databases help to capture and define the underlying biology behind different types of high-throughput experimental data and to understand the effects of small-molecule drug compounds in human tissues, it says.
GeneGo provides systems biology solutions for a full range of applications in life science research and drug development, from pre-clinical discovery and new chemical entities through to clinical trials.